Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition
Executive Summary
Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.
You may also be interested in...
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Authorized Generic "Interim" Report From FTC Offers Little Legislative Guidance
FTC commissioners issue separate statements on a report that does not address the long-term effects of authorized generics.